Member Info for sailorgirl

I think we can take it that this board has pretty well agreed that AVA6k must be working at this stage in the trial. What is not known is whether the drug will eventually prove to be commercially successful and this may only be confirmed when the trial results are eventually revealed later this year. What is pretty sure is that if further progress is to be made, it is most likely that a serious fund raising exercise will have to be undertaken if the drug is to be kept in house.

Against this background and given the strongly positive messages from AS, I find it bizarre that absolutely NONE of the directors have bought any shares since January 2019. When it comes to a fund raise the company might just find institutional interest less than enthusiastic if the directors haven’t shown any interest.

What I really don’t understand about this company is why NONE of the directors haven’t bought any shares in recent years. For a company with such apparently outstanding prospects, albeit highly dependent on the outcome of clinical trials, I would have expected at least some of them to take advantage of the SP weaknesses that have occurred all too frequently. Strange.

Just to get the usual cynics out there going, the AV SP has now broken out from a very neat flag formation. Price prediction looks like 240p which I seem to recall was well on the way to the all time high for Avacta.

We shall see and no doubt this post will bring about a fair amount of abuse full comment.

Pretty obvious that the AGM statement was a ‘for sale’ sign. The business has been cleaned up, is making good gross profits and generating cash. When Christopher Mills did that video interview of the companies he had investments in a while ago (I think he has 29% of CIR) he speculated that a larger company might buy it to consolidate its business with their own and eliminate duplicated overheads. Makes a lot of sense and could happen sooner than we think.

Not so much rampy as clearly very knowledgable. Well argued case for a significantly higher SP.
Let us hope the market takes note - and not predators.

It is Easter and the sun is shining - and Avacta seems to be emerging from a dark period with renewed confidence. I first became a shareholder exactly 2 years ago primarily because of my interest in the potential of the AVA6000 chemotherapy technology. I have now built up a holding of 2mill shares at an average price nicely below the current SP.

I have no intention of selling anytime soon but I believe we face a risk of a predatory bid that might be difficult for the directors and shareholders to defend. This is because of the weak shareholder base. On a fully diluted basis, the directors and 3 institutional shareholders only have 15% of the equity with the balance being held by multiple smaller shareholders. I would suggest that if someone were to offer a premium of say 40% over SP, then as is usual with such matters, many shareholders might be tempted by ‘the bird in hand’ rather than waiting for the results of the first in human trial.

I very much hope this does not happen but the recent GSK/Sierra deal shows the price potential for attractive oncology targets - and Avacta has much greater potential than Sierra which went for £1.5Bn compared with our present MC of £320m.

We face an exciting few months until the results are revealed and let us hope the SP rises steadily in anticipation. A positive result would undoubtedly see the SP well over the historic high and £5ps has a nice ring to it……..

Eco Buildings Group was formed 30 November 2021 and is clearly the target company with Linden as a 25% shareholder. Look at Companies House.

All very interesting. Has anyone noticed that Linden Holdings Limited - owned by Vistry (previously ka Bovis) has a 25% stake in the target company...........